Nice find.
Why doesn’t the company announce/promote these new initiatives to the ASX?
Probably doesn’t deserve a price sensitive announcement, but it would demonstrate growth/progress/efficiencies in their suite of products to healthcare/pharmacy.
Surely they can afford an ASX publication outside of financial reporting obligations.
Is this enhancement and rebranding to PlusOne the FredIT killer?
With more functionality to pharmacy, SaaS fees should get an incremental increase.
Poured another drink from the top shelf after this week.
Where does the market see full valuation?
$250M in the rear view mirror, now $300M.
Is $500M on the 12 month horizon?
Will have to replace some bottles soon.
Add to My Watchlist
What is My Watchlist?
